Komori
PRISM BioLab (206A) · RiskFirst stated

Foreign Exchange Rate Fluctuation Risk Associated with Overseas Transactions

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Impact of Foreign Exchange Movements and Foreign-Currency-Denominated Transactions on Business PerformanceA theme 478 companies write about · 416 as a headwind · 20 as a tailwind

The whole theme swung hardest in 2025: 71 of 159 companies on the "Worse" side.

4 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 195 companies compared. The sentences above are computed from all 195.Comparing 200 of the theme's 491 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「We conduct numerous transactions with overseas pharmaceutical companies and CROs (contract research organizations), with receipts and payments settled in foreign currencies. Accordingly, fluctuations in foreign exchange rates will affect our operating results and financial position.」

    Foreign exchange risk arising from foreign-currency transactions with overseas pharmaceutical companies and CROs was newly identified as a key risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PRISM BioLab yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.